Asparaginase-like protein 1 is an independent prognostic marker in primary endometrial cancer, and is frequently lost in metastatic lesions

被引:18
作者
Fonnes, Tina [1 ,2 ]
Berg, Hege F. [1 ,2 ]
Bredholt, Therese [1 ,2 ]
Edqvist, Per-Henrik D. [3 ,4 ]
Sortland, Kristina [5 ]
Berg, Anna [1 ,2 ]
Salvesen, Helga B. [1 ,2 ]
Akslen, Lars A. [6 ,7 ]
Werner, Henrica M. J. [1 ,2 ]
Trovik, Jone [1 ,2 ]
Tangen, Ingvild L. [1 ,2 ]
Krakstad, Camilla [1 ,2 ]
机构
[1] Univ Bergen, Ctr Canc Biomarkers, Dept Clin Sci, Bergen, Norway
[2] Haukeland Hosp, Dept Obstet & Gynecol, Bergen, Norway
[3] Uppsala Univ, Dept Immunol Genet & Pathol, Uppsala, Sweden
[4] Sci Life Lab, Uppsala, Sweden
[5] Univ Bergen, Dept Biomed, Bergen, Norway
[6] Haukeland Hosp, Dept Pathol, Bergen, Norway
[7] Univ Bergen, Ctr Canc Biomarkers, Dept Clin Med, Sect Pathol, Bergen, Norway
关键词
Endometrial carcinoma; Hysterectomy; Prognostic; Biomarker; ASRGLI; EPITHELIAL-MESENCHYMAL TRANSITION; ESTROGEN-RECEPTOR-ALPHA; PI3K ALTERATIONS; OVARIAN-CANCER; CARCINOMA; EXPRESSION; TUMORS; SYNTHETASE; BIOMARKERS; THERAPY;
D O I
10.1016/j.ygyno.2017.10.025
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. Loss of Asparaginase-like protein 1 (ASRGLI) has been suggested as a prognostic biomarker in endometrial carcinoma. Our objective was to validate this in a prospectively collected, independent patient cohort, and evaluate ASRGLI expression in endometrial carcinoma precursor lesion and metastases. Methods. 782 primary endometrial carcinomas, 90 precursor lesions (complex atypical hyperplasia), and 179 metastases (from 87 patients) were evaluated for ASRGLI expression by immunohistochemistry in relation to clinical and histopathological data. ASRGLI mRNA level was investigated in 237 primary tumors and related to survival and ASRGLI protein expression. Results. Low expression of ASRGLI protein and ASRGLI mRNA predicted poor disease specific survival (P < 0.001). In multivariate survival analyses ASRGLI had independent prognostic value both in the whole patient cohort (Hazard ratio (HR): 1.53, 95% confidence interval (CI): 1.04-2.26, P = 0.031) and within the endometrioid subgroup (HR: 2.64, CI: 1.47-4.74, P = 0.001). Low ASRGLI expression was less frequent in patients with low grade endometrioid primary tumors compared to high grade endometrioid and non-endometrioid primary tumors, and ASRGLI was lost in the majority of metastatic lesions. Conclusions. In a prospective setting ASRGLI validates as a strong prognostic biomarker in endometrial carcinoma. Loss of ASRGL1 is associated with aggressive disease and poor survival, and is demonstrated for the first time to have independent prognostic value in the entire endometrial carcinoma, patient population. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:197 / 203
页数:7
相关论文
共 32 条
[1]   Asparagine Synthetase Expression and Phase I Study With L-Asparaginase Encapsulated in Red Blood Cells in Patients With Pancreatic Adenocarcinoma [J].
Bachet, Jean-Baptiste ;
Gay, Fabien ;
Marechal, Raphael ;
Galais, Marie-Pierre ;
Adenis, Antoine ;
Salako, David ;
Cros, Jerome ;
Demetter, Pieter ;
Svrcek, Magali ;
Bardier-Dupas, Armelle ;
Emile, Jean-Francois ;
Hammel, Pascal ;
Ebenezer, Christelle ;
Berlier, Willy ;
Godfrin, Yann ;
Andre, Thierry .
PANCREAS, 2015, 44 (07) :1141-1147
[2]   Advances in the Management of Recurrent Endometrial Cancer [J].
Bradford, Leslie S. ;
Rauh-Hain, Jose Alejandro ;
Schorge, John ;
Birrer, Michael J. ;
Dizon, Don S. .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2015, 38 (02) :206-212
[3]   A novel asparaginase-like protein is a sperm autoantigen in rats [J].
Bush, LA ;
Herr, JC ;
Wolkowicz, M ;
Sherman, NE ;
Shore, A ;
Flickinger, CJ .
MOLECULAR REPRODUCTION AND DEVELOPMENT, 2002, 62 (02) :233-247
[4]  
Cancer Registry of Norway, 2015, CANC NORW CANC INC M
[5]   The Human Asparaginase-like Protein 1 hASRGL1 Is an Ntn Hydrolase with β-Aspartyl Peptidase Activity [J].
Cantor, Jason R. ;
Stone, Everett M. ;
Chantranupong, Lynne ;
Georgiou, George .
BIOCHEMISTRY, 2009, 48 (46) :11026-11031
[6]   ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up [J].
Colombo, N. ;
Creutzberg, C. ;
Amant, F. ;
Bosse, T. ;
Gonzalez-Martin, A. ;
Ledermann, J. ;
Marth, C. ;
Nout, R. ;
Querleu, D. ;
Mirza, M. R. ;
Sessa, C. .
ANNALS OF ONCOLOGY, 2016, 27 (01) :16-41
[7]   Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].
Colombo, N. ;
Preti, E. ;
Landoni, F. ;
Carinelli, S. ;
Colombo, A. ;
Marini, C. ;
Sessa, C. .
ANNALS OF ONCOLOGY, 2013, 24 :33-38
[8]   Validation of New Cancer Biomarkers: A Position Statement from the European Group on Tumor Markers [J].
Duffy, Michael J. ;
Sturgeon, Catharine M. ;
Soletormos, Gyorgy ;
Barak, Vivian ;
Molina, Rafael ;
Hayes, Daniel F. ;
Diamandis, Eleftherios P. ;
Bossuyt, Patrick M. M. .
CLINICAL CHEMISTRY, 2015, 61 (06) :809-820
[9]   Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma [J].
Edqvist, Per-Henrik D. ;
Huvila, Jutta ;
Forsstrom, Bjorn ;
Talve, Lauri ;
Carpen, Olli ;
Salvesen, Helga B. ;
Krakstad, Camilla ;
Grenman, Seija ;
Johannesson, Henrik ;
Ljungqvist, Oscar ;
Uhlen, Mathias ;
Ponten, Fredrik ;
Auranen, Annika .
GYNECOLOGIC ONCOLOGY, 2015, 137 (03) :529-537
[10]  
Evtimova V, 2004, INT J ONCOL, V24, P33